
Kendrick, Michael J.
Levels of Empowerment, Planet Advocacy, Issue Number 7, March 2004, pp 6-7.
Tuesday, May 20, 2003
Leading Drugs for Psychosis Come Under New Scrutiny Front page feature article in today's
New York Times - "They were billed as near wonder drugs, much safer and more effective in treating schizophrenia than anything that had come before. For many years, it seemed that the excitement was fully warranted. There were remarkable stories of recovery. And the new generation of antipsychotic drugs, called atypicals, seemed to have few of the side effects commonly seen with high doses of older medications for psychosis. ... But 14 years after the first of the drugs entered the market, researchers are questioning whether they are quite as miraculous — or benign — as originally advertised." [Viewing
New York Times resources requires registration, which is free].
Public Reporting on Quality in The United States and The UK Health Affairs article at
Medscape - "...Problems, challenges, obstacles, and innovations mark the trail, but there is incremental progress toward widespread use of quality report cards in the United States and the United Kingdom.... In the United States a strong emphasis on informing consumer choice and controlling costs has guided reporting. Different traditions and incentives are at work across the Atlantic. The two countries have much to learn from each other as they move toward greater accountability and quality in health care." [Viewing
Medscape resources requires registration, which is free].
Copyright 2003 © Bill Davis.
IIMHL Update is a project done in collaboration with MHCA and
the Centre
for Community Change International. IIMHL Update is powered by Radio Userland.